Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier.
The purpose of these studies was to determine the mechanism(s) whereby paclitaxel (PTX), is taken up by cancer cells, once encapsulated into synthetic/reconstituted high density lipoprotein (rHDL). The uptake of PTX was found to be facilitated by the scavenger receptor type B-1 (SR-B1) when drug-loaded rHDL particles were incubated with cells that express the SRB1 receptor. Studies with double-labeled, PTX containing rHDL nanoparticles showed that prostate cancer (PC-3) cells incorporated PTX primarily via a selective (SR-B1 type) uptake mechanism. In the presence of a 10-fold excess of plasma HDL, PTX uptake decreased to 30% of the control. These findings suggest that the incorporation of lipophilic drugs by cancer cells from rHDL nanoparticles is facilitated by a receptor mediated (SR-B1) mechanism.
Mooberry
Linda K
LK
Department of Molecular Biology and Immunology, University of North Texas Health Science Center, Fort Worth TX, USA.
Nair
Maya
M
Paranjape
Sulabha
S
McConathy
Walter J
WJ
Lacko
Andras G
AG
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000493:pharmacokinetics; D045744:Cell Line, Tumor; D004337:Drug Carriers / Q000737:chemistry*; D016503:Drug Delivery Systems; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood / Q000737:chemistry*; D008297:Male; D053758:Nanoparticles; D017239:Paclitaxel / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism; D051122:Scavenger Receptors, Class B / Q000378:metabolism
D000972:Antineoplastic Agents, Phytogenic; D004337:Drug Carriers; D008075:Lipoproteins, HDL; C495124:SCARB1 protein, human; D051122:Scavenger Receptors, Class B; D017239:Paclitaxel